Caliway is dedicated to pioneering small-molecule medications catering to aesthetics and various diseases, tapping into a burgeoning market valued at over $10 billion.
Our flagship compound, CBL-514, showcased remarkable efficacy in Phase 2 clinical trials, notably reducing subcutaneous fat by an average of 312mL in treated areas while also demonstrating promising improvements in cellulite without significant systemic side effects. Furthermore, our pipeline boasts CBL-514D, earmarked for addressing Dercum's disease, a rare condition characterized by painful lipoma growths.
For more information, please visit: Caliway.com.tw/en
Company Details
- Employees
- 21
- Founded
- -
- Address
- 汐止區新台五路一段99號32樓之9, 新北市,22175,taiwan, Province Of China
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- caliway.com.tw
- Keywords
- Show more similar pages.
- HQ
- 新北市
Caliway Biopharmaceuticals Questions
Caliway Biopharmaceuticals's website is caliway.com.tw
Caliway Biopharmaceuticals's LinkedIn profile is https://tw.linkedin.com/company/caliway
Caliway Biopharmaceuticals has
21 employees.
View email and phone details for 21
employees at Caliway Biopharmaceuticals.
Caliway Biopharmaceuticals's industry is
Pharmaceutical Manufacturing
Caliway Biopharmaceuticals's top competitors are
Triveni Bio,
Enara Bio,
Kailera Therapeutics,
Mindpeak Gmbh,
Nym,
Aktis Oncology,
Onkure Therapeutics,
Loqus23 Therapeutics Ltd,
Nusano,
Biohaven.
Caliway Biopharmaceuticals's categories are Pharmaceutical Manufacturing
Caliway Biopharmaceuticals's founding year is 2012
